Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

(R) 9b

Next Previous
Drug Profile

(R) 9b

Alternative Names: (R)-9b; Mahatinib

Latest Information Update: 07 Feb 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator TechnoGenesys
  • Class Antineoplastics; Small molecules
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Prostate cancer

Most Recent Events

  • 03 Dec 2024 TechnoGenesys has patent protection for (R) 9b in USA, China, Europe and India, prior to November 2024 (TechnoGenesys pipeline, December 2024)
  • 21 Nov 2024 Preclinical trials in Prostate cancer(Hormone refractory) in USA (PO) (TechnoGenesys's pipeline, December 2024)
  • 21 Nov 2024 TechnoGenesys plans a phase I PHAROS trial for Prostate cancer(Metastatic disease, Hormone refractory) in USA (PO) in March 2025 (NCT06705686)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top